Evidence map›Paper›PMID 38195982›Full record

ArticleBone marrow transplantation2024

Allogeneic hematopoietic cell transplantation is equally effective in secondary acute lymphoblastic leukemia (ALL) compared to de-novo ALL-a report from the EBMT registry.

A Sadowska-Klasa, J M Zaucha, M Labopin, J H Bourhis, D Blaise, I Yakoub-Agha, U Salmenniemi, J Passweg, N Fegueux, T Schroeder and 4 more

Abstract read
PubMed Publisher
In one paragraph

Article in Bone marrow transplantation, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

A Sadowska-KlasaDepartment of Hematology and Transplantology, Medical University of Gdańsk, Gdańsk, Poland. a.sadowska@gumed.edu.pl.ORCID 0000-0002-7752-5839
J M ZauchaDepartment of Hematology and Transplantology, Medical University of Gdańsk, Gdańsk, Poland. jzaucha@gumed.edu.pl.
M LabopinDepartment of Hematology, Sorbonne University, Hopital Saint Antoine, Paris, France.ORCID 0000-0003-4514-4748
J H BourhisDepartment of Hematology, Gustave Roussy Cancer Campus, BMT Service, Villejuif, France.
D BlaiseProgramme de Transplantation & Therapie Cellulaire, Centre de Recherche en Cancérologie de Marseille, Institut Paoli Calmettes, Marseille, France.ORCID 0000-0002-5684-9447
I Yakoub-AghaCHU de Lille, LIRIC, INSERM U995, Université de Lille, Lille, France.ORCID 0000-0003-4524-8782
U SalmenniemiHUCH Comprehensive Cancer Center, Stem Cell Transplantation Unit, Helsinki, Finland.
J PasswegUniversity Hospital, Hematology, Basel, Switzerland.ORCID 0000-0001-7092-3351
N FegueuxCHU Lapeyronie, Département d'Hématologie Clinique, Montpellier, France.
T SchroederDepartment of Bone Marrow Transplantation, University Hospital, Essen, Germany.
S GiebelDepartment of Bone Marrow Transplantation and Onco-Hematology, Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice Branch, Gliwice, Poland.
E BrissotService d'Hématologie Clinique et Thérapie Cellulaire, Hôpital Saint-Antoine, AP-HP, Sorbonne University, and INSERM UMRs 938, Paris, France.
F CiceriOspedale San Raffaele, Haematology and BMT, Milan, Italy.ORCID 0000-0003-0873-0123
M MohtyDepartment of Hematology, Sorbonne University, Hopital Saint Antoine, Paris, France.ORCID 0000-0002-7264-808X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Secondary acute lymphoblastic leukemia (s-ALL) comprises up to 10% of ALL patients. However, data regarding s-ALL outcomes is limited. To answer what is the role of allogeneic hematopoietic cell transplantation (HCT) in s-ALL, a matched-pair analysis in a 1:2 ratio was conducted to compare outcomes between s-ALL and de novo ALL (dn-ALL) patients reported between 2000-2021 to the European Society for Blood and Marrow Transplantation registry. Among 9720 ALL patients, 351 (3.6%) were s-ALL, of which 80 were in first complete remission (CR1) with a known precedent primary diagnosis 58.8% solid tumor (ST), 41.2% hematological diseases (HD). The estimated 2-year relapse incidence (RI) was 19.1% (95%CI: 11-28.9), leukemia-free survival (LFS) 52.1% (95%CI: 39.6-63.2), non-relapse mortality (NRM) 28.8% (95%CI: 18.4-40), GvHD-free, relapse-free survival (GRFS) 39.4% (95%CI: 27.8-50.7), and overall survival (OS) 60.8% (95%CI: 47.9-71.4), and did not differ between ST and HD patients. In a matched-pair analysis, there was no difference in RI, GRFS, NRM, LFS, or OS between s-ALL and dn-ALL except for a higher incidence of chronic GvHD (51.9% vs. 31.4%) in s-ALL. To conclude, patients with s-ALL who received HCT in CR1 have comparable outcomes to patients with dn-ALL.

Indexed as

Graft vs Host DiseaseHematopoietic Stem Cell TransplantationLeukemia, Myeloid, AcutePrecursor Cell Lymphoblastic Leukemia-LymphomaHumansRecurrenceRegistriesRetrospective StudiesTransplantation Conditioning

Identifiers

PMID38195982

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.